JAK inhibitor safety: Weighing up the data and understanding the risks
What you need to know
A number of JAK inhibitors are now approved for the treatment of rheumatic diseases in different settings, but questions remain about their long-term safety profiles and overall place in therapy.
Take a look below for in-depth discussion of the potential risks associated with JAK inhibitors and what these mean for rheumatologists, as well as news on the latest safety data and approvals for this class of drugs.
Expert discussion on the ORAL Surveillance results
Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.
Following the results of the ORAL Surveillance trial, which demonstrated increased rates of adverse events in people taking JAK inhibitors, Victoria Ruffing provides guidance on how to talk to patients about the risks associated with these medications.
The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with RA at high CV risk, show the ORAL Surveillance results.
“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.
AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis. *in patients with an inadequate response or intolerance to at least one tumor necrosis factor inhibitor.
AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis. *in patients with an inadequate response or intolerance to at least one tumor necrosis factor inhibitor.